IMM-101 is under clinical development by Immodulon Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMM-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMM-101 overview

IMM-101 is under development for the treatment of metastatic pancreatic cancer, metastatic melanoma, pancreatic ductal adenocarcinoma, metastatic colorectal cancer and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and for the prevention of the COVID-19 associated infections and severe respiratory infections in cancer patients at increased risk of exposure. It is administered intradermally as a suspension. IMM-101 is a vaccine that comprises of heat killed whole cell mycobacterium from a strain of Mycobacterium obuense. It was also under development for the treatment of breast cancer, lung cancer, leiomyosarcoma, dedifferentiated liposarcoma and cholangiocarcinoma

Immodulon Therapeutics overview

Immodulon Therapeutics (Immodulon) is a biopharmaceutical company that develops novel immunotherapeutic products for cancer. The company lead product such as IMM-101 and IMM-201. Its IMM-101 is a heat killed whole cell mycobacterium’s intradermal formulation which helps to provoke delayed hypersensitivity response. It provides conducts clinical study to evaluate the safety and tolerability of intradermal IMM-101 in adult melanoma cancer patients. Immodulon also develops immunotherapeutic options as adjunctive therapy for certain cancers. The company has ongoing collaborations for the use of mycobacterial immunomodulators in the treatment of persistent chronic inflammation such as mood disorders, tuberculosis, post traumatic stress disorder, and others. Immodulon is headquartered in Uxbridge, the UK.

For a complete picture of IMM-101’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.